<DOC>
	<DOCNO>NCT01738360</DOCNO>
	<brief_summary>Primary objective : - To investigate safety tolerability ATO IV infusion patient SLE , - To determine maximum tolerate dose ATO . Secondary objective : - Evaluation clinical biological response SLE ATO , - Time relapse case positive response , - Determination efficacy , - Pharmacokinetic study ATO .</brief_summary>
	<brief_title>Phase 2a Study Evaluating Arsenic Trioxide ( ATO ) Systemic Lupus ( SLE ) ( Protocol LUPSENIC )</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>Systemic Lupus meeting ACR ( American College Rheumatology ) criterion , progressive either SLEDAI activity score ≥ 4 , despite corticosteroid therapy ≥ 10 mg / associate hydroxychloroquine ( absence contraindication intolerance ) / immunosuppressive treatment stable dose , Insured , Availability hospitalization require protocol ( conventional daily hospitalization ) . Inability give sign informed consent form , Performans status &gt; 2 QTcorrected space treatment &gt; 0.45 second Hemoglobin le 11g/dL Neutrophils rate 1 200 / mm3 Platelets rate 100 Giga / mm3 Previous history arrhythmia heart rhythm disorder rhythm trouble refer cardiologist Heart disorder ( progressive pericarditis , valvular disease , ... ) accord cardiologist Family previous history arrhythmia Taking drug potentially prolong QT Hypersensitivity active substance Trisenox® excipients Serum potassium ≤ 4 milliequivalent / L Magnesemia ≤ 1,8 mg / dl Increase corticosteroids beyond 20 mg / day within 15 day inclusion Immunosuppressive treatment , thalidomide introduce within last 3 month Biotherapy ( rituximab , belimumab , ... ) introduce within 6 month prior inclusion Pregnancy lactation For woman childbearing age , men partner : unless effective contraception duration participation study 7 month Creatinine clearance &lt; 50 ml / min , Hepatocellular insufficiency ( TP &lt; 50 % ) , / AST ( aspartate aminotransferase ) / ALT ( alanine aminotransferase ) / ALP ( alkaline phosphatase ) &gt; 2N HBsAg positive , DNA detectable HbS Infection HIV , HBV ( hepatitis B virus ) HCV ( hepatitis C virus ) Renal progressive central neurological impairment possible alternative therapeutic ( discussed principal investigator scientific board meeting ) Peripheral neuropathy Unweaned alcoholism Minor Patients old 65 year Patient professionally expose arsenic ( clean electronic circuit example ) Guardianship patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Arsenic trioxide</keyword>
	<keyword>Systemic Lupus</keyword>
	<keyword>clinically</keyword>
	<keyword>biologically active</keyword>
</DOC>